Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
Clinical trial NCT07100392 · RECRUITING
Trial details
- NCT number
- NCT07100392
- Sponsor
- Fudan University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-14
- Primary completion
- 2027-08-01
- Enrollment
- 141
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.